Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
J Van Asperen, O Van Tellingen, A Sparreboom… - British journal of …, 1997 - nature.com
J Van Asperen, O Van Tellingen, A Sparreboom, AH Schinkel, P Borst, WJ Nooijen…
British journal of cancer, 1997•nature.comInhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-
glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of
paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results
encourage further research on the development of a clinically useful oral formulation of
paclitaxel.
glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of
paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results
encourage further research on the development of a clinically useful oral formulation of
paclitaxel.
Abstract
Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results encourage further research on the development of a clinically useful oral formulation of paclitaxel.
nature.com